新型抗抑郁剂阿戈美拉汀治疗老年性卒中后抑郁的疗效研究

目的探讨阿戈美拉汀治疗老年性卒中后抑郁的有效性。方法将80例老年性卒中后抑郁患者分为治疗组、对照组各40例;治疗组给予阿戈美拉汀联合常规脑血管病药物治疗,对照组给予舍曲林联合常规脑血管病药物治疗;治疗第l、2、4、6周,应用Hamilton抑郁量表（HAMD）、神经功能缺损量表（NIHSS）、日常生活能力Barthel指数（BI）评定其疗效。结果治疗组与对照组HAMD、NIHSS、BI指数评分均有显著改善,但两组差异无统计学意义（P〉0.05）。结论阿戈美拉汀治疗卒中后抑郁疗效显著,且与舍曲林无差异。

Study on effect of new antidepressant agomelatine treatment of senile post-stroke depression

Objective To investigate the effectiveness of agomelatine treatment of senile post-stroke depression.Methods Eighty cases of patients of senile post-stroke depression were divided into treatment group, control group,with 40 cases in each. The treatment group was given agomelatine combined with routine cerebrovascular disease drug treatment, the control group received sertraline combined with routine cerebrovascular disease drug treatment; In the treatment of 1, 2, 4, 6 weeks, used Hamilton Depression Scale（HAMD）, neural function defect scale（NIHSS）, ability of daily life Barthel（BI） assessment index. Results The HAMD, NIHSS, BI index scores of treatment group and the control group were significantly improved, but had no significant difference between two groups（P〉0.05）. Conclusion Agomelatine has significant effect in treatment of senile post-stroke depression,and is no difference with sertraline.